Xeris Biopharma Holdings, Inc. (XERS) Form 8-K — Aug 6, 2026
Xeris Biopharma reported strong second quarter 2026 results with total revenue of $92.1 million, up 29% year-over-year, driven by a 34% increase in net product revenue to $91.0 million. The growth was primarily fueled by Recorlev, which saw net revenue jump 81% to approximately $57 million. The company tightened its full-year 2026 revenue guidance to $385-390 million, reflecting confidence in its commercial execution and product portfolio.
Key figures
- Revenue
- 92100
- Debt Amount
- 188807
- Revenue Yoy
- 29
- Cash Position
- 121747
- Shares Outstanding
- 182320306
- Gross Margin
- 86
- Debt Reduction
- 23
- Guidance Range
- 385-390 million
- Adjusted Ebitda
- 19273
- Recorlev Revenue
- 56780
- Recorlev Revenue Yoy
- 81
- Shares Issued In Conversion
- 3.6
- Shares Issued In Debt Exchange
- 5
Price after filing
1 day: -1.0%7 days: +1.7%30 days: +4.2%
Close on the filing date to close N calendar days later (from $8.19). Historical, not a forecast.
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.